INVO Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (the "Company") on June 20, 2024, covering events occurring on June 13, 2024, and June 18, 2024. The Company is a Nevada corporation with its principal executive offices in Sarasota, Florida, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "INVO."
Key Financial Metrics
This filing does not contain specific financial statements, revenue, profit, cash flow, or debt figures. The only financial metric referenced is the Company's historical non-compliance with Nasdaq's Listing Rule 5550(b)(1) (the "Equity Rule"), which requires stockholders' equity to meet or exceed $2,500,000. The filing notes that the Company reported stockholders' equity below this threshold for the period ended December 31, 2023.
Material Changes and Events
- Nasdaq Listing Status (Item 3.01): On June 18, 2024, the Nasdaq Hearing Panel granted the Company's request for continued listing. This decision is conditional upon the Company demonstrating compliance with Nasdaq's Initial Listing Rule (Rule 5505) by October 14, 2024. The Company previously received a delisting notice on April 17, 2024, due to insufficient stockholders' equity.
- Asset Transfer (Item 8.01): On June 13, 2024, the Company's subsidiary, Wood Violet Fertility, LLC, transferred ownership of Wisconsin Fertility and Reproductive Surgery Associates, S.C. ("WFRSA"), to Dr. Donna Baldwin. Concurrently, Dr. Elizabeth Pritts, the former owner and director of WFRSA, separated from employment.
Outlook, Management Commentary, and Risks
Management believes the extension granted by Nasdaq until October 14, 2024, provides sufficient time to complete the proposed acquisition of NAYA Biosciences, Inc., which is expected to help satisfy initial listing requirements. Regarding the transfer of WFRSA, the Company stated that all other transaction documents remain in full force and effect. Management asserts that the transfer and separation of Dr. Pritts are not expected to impact patient care, operational performance, or the Company's financial condition or results of operations.
Key Facts for Investor Verification
- Verify the Company's ability to meet Nasdaq's Initial Listing Rule (Rule 5505) requirements by the October 14, 2024 deadline to avoid delisting.
- Confirm the status and expected closing date of the proposed acquisition of NAYA Biosciences, Inc., which is central to the Company's compliance strategy.
- Monitor future filings for any updates on the Company's stockholders' equity position relative to the $2,500,000 threshold.
- Review subsequent reports to ensure the transfer of WFRSA has no unforeseen financial or operational impacts despite management's current assessment.